279 related articles for article (PubMed ID: 19459657)
1. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
3. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
[TBL] [Abstract][Full Text] [Related]
4. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
6. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458).
Liu L; Siegmund A; Xi N; Kaplan-Lefko P; Rex K; Chen A; Lin J; Moriguchi J; Berry L; Huang L; Teffera Y; Yang Y; Zhang Y; Bellon SF; Lee M; Shimanovich R; Bak A; Dominguez C; Norman MH; Harmange JC; Dussault I; Kim TS
J Med Chem; 2008 Jul; 51(13):3688-91. PubMed ID: 18553959
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase.
Sheth PR; Watowich SJ
Biochemistry; 2005 Aug; 44(33):10984-93. PubMed ID: 16101282
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
[TBL] [Abstract][Full Text] [Related]
11. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.
Zimmer Y; Vaseva AV; Medová M; Streit B; Blank-Liss W; Greiner RH; Schiering N; Aebersold DM
Cancer Lett; 2010 Mar; 289(2):228-36. PubMed ID: 19783361
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.
Solowiej J; Bergqvist S; McTigue MA; Marrone T; Quenzer T; Cobbs M; Ryan K; Kania RS; Diehl W; Murray BW
Biochemistry; 2009 Jul; 48(29):7019-31. PubMed ID: 19526984
[TBL] [Abstract][Full Text] [Related]
15. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
16. An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors.
Accornero P; Lattanzio G; Mangano T; Chiarle R; Taulli R; Bersani F; Forni PE; Miretti S; Scuoppo C; Dastrù W; Christensen JG; Crepaldi T; Ponzetto C
Clin Cancer Res; 2008 Apr; 14(7):2220-6. PubMed ID: 18381964
[TBL] [Abstract][Full Text] [Related]
17. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.
Solowiej J; Chen JH; Zou HY; Grant SK; Murray BW
ACS Chem Biol; 2013 May; 8(5):978-86. PubMed ID: 23441851
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel type II c-Met inhibitors based on BMS-777607.
Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
Eur J Med Chem; 2014 Jun; 80():254-66. PubMed ID: 24792774
[TBL] [Abstract][Full Text] [Related]
19. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.
Liang Z; Ding X; Ai J; Kong X; Chen L; Chen L; Luo C; Geng M; Liu H; Chen K; Jiang H
Org Biomol Chem; 2012 Jan; 10(2):421-30. PubMed ID: 22108637
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
